<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956640</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-RAS-20001</org_study_id>
    <secondary_id>2021-000595-12</secondary_id>
    <secondary_id>J3M-OX-JZQA</secondary_id>
    <nct_id>NCT04956640</nct_id>
  </id_info>
  <brief_title>Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)</brief_title>
  <official_title>A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether the study drug, LY3537982, is safe and&#xD;
      effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must&#xD;
      have already received or were not able to tolerate the standard of care. The study will last&#xD;
      up to approximately 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability, and&#xD;
      preliminary efficacy of oral LY3537982 in patients with KRAS G12C-mutant solid tumors.&#xD;
&#xD;
      This study will be conducted in 2 parts, Part 1a is a dose escalation and Part 1b is a dose&#xD;
      expansion. Part 1a will establish a recommended Phase 2 dose. Part 1b will have multiple arms&#xD;
      of either monotherapy or in combination with other drugs.&#xD;
&#xD;
      KRAS G12C mutations will be identified through standard of care testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy</measure>
    <time_frame>Cycle 1 (21 Days)</time_frame>
    <description>Measured by the number of patients with dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents</measure>
    <time_frame>Cycle 1 (21 Days)</time_frame>
    <description>Measured by the number of patients with dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Objective response rate (ORR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Duration of Response (DOR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Time to response (TTR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>TTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Disease control rate (DCR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Progression-free survival (PFS)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Overall survival (OS)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LY3537982: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Predose estimated up to 2 years</time_frame>
    <description>PK: AUC of LY3537982</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the PK properties of LY3537982: Maximum drug concentration (Cmax)</measure>
    <time_frame>Predose estimated up to 2 years</time_frame>
    <description>PK: Cmax of LY3537982</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Colorectal Neoplams</condition>
  <condition>Endometrial Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>LY3537982 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3537982 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3537982 administered orally either alone or with another investigational agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3537982</intervention_name>
    <description>Oral</description>
    <arm_group_label>LY3537982 (Dose Escalation)</arm_group_label>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Oral</description>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
    <other_name>Verzenio</other_name>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
    <other_name>Tyvyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temuterkib</intervention_name>
    <description>Oral</description>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
    <other_name>LY3214996</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3295668</intervention_name>
    <description>Oral</description>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>LY3537982 (Dose Expansion)</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients have measurable disease per Response Evaluation Criteria in Solid Tumors&#xD;
             version 1.1 (RECIST v1.1).&#xD;
&#xD;
          -  Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or&#xD;
             circulating tumor deoxyribonucleic acid (DNA).&#xD;
&#xD;
          -  Participants must have a histological or a cytologically proven diagnosis of locally&#xD;
             advanced, unresectable, and/or metastatic cancer and meet cohort-specific criteria.&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Have adequate organ function.&#xD;
&#xD;
          -  Have discontinued all previous treatments for cancer with resolution of any&#xD;
             significant ongoing adverse events (AEs).&#xD;
&#xD;
          -  Must be able to swallow capsule/tablet.&#xD;
&#xD;
          -  Agree and adhere to contraceptive use, if applicable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease suitable for local therapy administered with curative intent.&#xD;
&#xD;
          -  Have an active, ongoing, or untreated infection.&#xD;
&#xD;
          -  Have a serious pre-existing medical condition(s) that, in the judgment of the&#xD;
             investigator, would preclude participation in this study.&#xD;
&#xD;
          -  Have a serious cardiac condition.&#xD;
&#xD;
          -  Have a second active primary malignancy or have been diagnosed and/or treated for an&#xD;
             additional malignancy within 3 years prior to enrollment.&#xD;
&#xD;
          -  Have symptomatic central nervous system (CNS) malignancy or metastasis and/or&#xD;
             carcinomatous meningitis. Patients with treated CNS metastases are eligible for this&#xD;
             study if they are not currently receiving corticosteroids in excess of 10 milligrams&#xD;
             (mg) per day prednisone/prednisolone (or equivalent) and their disease is asymptomatic&#xD;
             and radiographically stable for at least 30 days.&#xD;
&#xD;
          -  Have received prior treatment with any KRAS G12C small molecule inhibitor, except in&#xD;
             certain scenarios where such prior therapy is allowed as per protocol.&#xD;
&#xD;
          -  For Cohorts B2, B3, and B5/C1, patients treated with drugs known to be strong&#xD;
             inhibitors or inducers of cytochrome P450 (CYP)3A.&#xD;
&#xD;
          -  The following patients will be excluded from Cohort B4:&#xD;
&#xD;
               -  Experienced certain serious side effects with prior immunotherapy.&#xD;
&#xD;
               -  Have an active autoimmune disease that has required systemic anti-autoimmune&#xD;
                  treatment in the past 2 years.&#xD;
&#xD;
               -  Have undergone prior allogeneic hematopoietic stem cell transplantation within&#xD;
                  the last 5 years.&#xD;
&#xD;
               -  Have received a live vaccine within 30 days prior to the first dose of study&#xD;
                  drug.&#xD;
&#xD;
          -  Pregnant, breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial through 180 days after the last dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Known allergic reaction against any of the components of the study treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melinda Willard, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-855-LOXO-305</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana Univ Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Community Health Network</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Mountain Region</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

